Pembrolizumab Medicine 03 June 2025 Extended indication Pembrolizumab in combination with paclitaxel with or without bevacizumab for second line or later treatment of platinum-resistant Ovarian cancer recurrent in adults and elderly. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Pembrolizumab Domain Oncology Reason of inclusion Indication extension IND Main indication Ovarian cancer Extended indication Pembrolizumab in combination with paclitaxel with or without bevacizumab for second line or later treatment of platinum-resistant Ovarian cancer recurrent in adults and elderly. Current proprietary name Already available biosimilars / generics Proprietary name Keytruda Manufacturer MSD Portfolio holder Mechanism of action PD-1 / PD-L1 inhibitor Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP No Submission date September 2025 Expected Registration March 2026 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration 400mg References NCT05116189 (KEYNOTE-B96/ENGOT-ov65) Additional remarks Expected patient volume per year Patient volume < 180 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References (1) IKNL; (2) expertopinie Additional remarks In Nederland werden in 2022 ongeveer 1.400 vrouwen gediagnosticeerd met eierstokkanker (1) (ovariumcarcinoom). Platinumresistent ovariumcarcinoom betreft tot 20% van de patiënten (280 patiënten) (2). Expected cost per patient per year Cost References Additional remarks Voor alle indicaties van pembrolizumab geldt een financieel arrangement. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks